Predictive value of biomarkers in steatohepatitis and fibrosis

Dilaver, İrem; saygın, ismail; tok, birgül; TAŞÇI, ŞÜKRİYE

doi:10.5455/annalsmedres.2023.02.047

Predictive value of biomarkers in steatohepatitis and fibrosis

ŞÜKRİYE TAŞÇI, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Dahiliye Anabilim Dalı, Trabzon, Türkiye)

İrem DİLAVER, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, Trabzon, Türkiye)

İsmail SAYGIN, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Trabzon, Türkiye)

Birgül TOK (Giresun Üniversitesi, Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Trabzon, Türkiye)

Annals of Medical Research

9 1

Yıl: 2023 Cilt: 30 Sayı: 4 Sayfa Aralığı: 493 - 498 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.02.047 İndeks Tarihi: 03-05-2023

Predictive value of biomarkers in steatohepatitis and fibrosis

Öz:

Aim: Non-alcoholic fatty liver disease (NAFLD) has recently become a significant public health problem around the world, with a reported prevalence of 25%. In this study, we aimed to investigate the utility of biochemical and hematological markers in the progres sion from hepatosteatosis to fibrosis and to examine their superiority to each other by comparing them with pathological scoring parameters. Materials and Methods: Pathological results of patients who underwent liver biopsy for different indications were reviewed retrospectively.Of these, 120 patients with fatty liver were selected and their biopsy specimens were re-evaluated according to the NAFLD Activity Score (NAS). The relationship between pathological scores and serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST to platelet ratio index (APRI), red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), RDW to platelet ratio (RPR), and gamma-glutamyl transpeptidase (GGT), RDW to platelet ratio (RPR), and gamma-glutamyl transpeptidase (GGT) was analyzed. Results: The results indicated that ALT, APRI, and GGT were significant predictors of nonalcoholic steatohepatitis (NASH), while GGT, APRI, and RPR were significant predictors of fibrosis. Additionally, ROC analysis confirmed the significant predictive value of APRI, RPR, and GGT in the diagnosis of fibrosis. Conclusion: Based on these results, we consider that GGT and APRI are better predic tors than other biomarkers.

Anahtar Kelime: Biomarkers Liver fibrosis Non-alcoholic steatohepatitis

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Younossi ZM. Non-alcoholic fatty liver disease – A global pub lic health perspective. J Hepatol [Internet]. 2019;70(3):531–44. Available from: https://doi.org/10.1016/j.jhep.2018.10.033.
2. Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: A grow ing public health problem in Turkey. Turkish J Gastroenterol. 2019;30(10):865–71.
3. Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic Fea tures Associated with Fibrosis in Nonalcoholic Fatty Liver Dis ease. Hum Pathol. 2004;35(2):196–9.
4. Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism [Internet]. 2016;65(8):1208–23. Available from: http://dx.doi.org/10.1016/j.metabol.2016.02.013.
5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epi demiology of nonalcoholic fatty liver disease—Meta-analytic as sessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
6. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol ogy. 2015;149(2):389-397.e10.
7. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non alcoholic fatty liver disease: Clinical prediction rules and blood based biomarkers. J Hepatol [Internet]. 2018;68(2):305–15. Avail able from: https://doi.org/10.1016/j.jhep.2017.11.013.
8. Tannapfel A, Denk H, Dienes HP, et al. Histopathological diag nosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458(5):511–23.
9. Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism [Internet]. 2016;65(8):1087–95. Available from: http://dx.doi.org/10.1016/j.metabol.2016.01.013.
10. Dharan NJ, Neuhaus J, Rockstroh JK, et al. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology. 2019;69(3):1135–50.
11. Kruger FC, Daniels CR, Kidd M, et al. APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. South African Med J. 2011;101(7):477–80.
12. Chen B, Ye B, Zhang J, et al. RDW to Platelet Ratio: A Novel Noninvasive Index for Predicting Hepatic Fibrosis and Cirrhosis in Chronic Hepatitis B. PLoS One. 2013;8(7):1–8.
13. Yilmaz, H., Yalcin, K. S., Namuslu, M.,et al. Neutrophil lymphocyte ratio (NLR) could be better predictor than C reactive protein (CRP) for liver fibrosis in non-alcoholic steato hepatitis (NASH). Annals of Clinical & Laboratory Science, 2015 45(3), 278-286.
14. Angulo P, Keach JC, Batts KP, et al.Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hep atology. 1999;30(6):1356–62.
15. Zhou JH, She ZG, Li HL, et al. Noninvasive evaluation of nonal coholic fatty liver disease: Current evidence and practice. World J Gastroenterol. 2019;25(11):1307–26.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and valida tion of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.
17. Zhou WJ, Yang J, Zhang G, et al. Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in non alcoholic fatty liver disease: A cross-sectional study. Medicine (Baltimore). 2019;98(30):e16565.
18. Adams LA, Sanderson S, Lindor KD, et al.The histologi cal course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8.
19. Paul Starr S, Raines D. Cirrhosis: Diagnosis, management, and prevention. Am Fam Physician. 2011;84(12):1353–9.
20. Verma S, Jensen D, Hart J, et al Predictive value of ALT lev els for non-alcoholic steatohepatitis (NASH) and advanced fi brosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33(9):1398–405.
21. Umegaki H. Sarcopenia and frailty in older patients with dia betes mellitus. 2016;293–9.
22. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in pa tients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.
23. Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Ger many. Aliment Pharmacol Ther. 2018;48(10):1109–16.
24. Jin W, Lin Z, Xin Y, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: A leading meta analysis. BMC Gastroenterol [Internet]. 2012;12(1):14. Availablefrom:http://www.biomedcentral.com/1471- 230X/12/14.
25. Pusuroglu H, Cakmak HA, Akgul O, et al. The prognostic value of admission red cell distribution width-to-platelet ra tio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Rev Port Cardiol [Internet]. 2015;34(10):597–606. Available from: http://dx.doi.org/10.1016/j.repc.2015.03.014.
26. Qiu L, Chen C, Li SJ, et al. Prognostic values of red blood cell distribution width, platelet count, and red cell distribution width-to-platelet ratio for severe burn injury. Sci Rep [Internet]. 2017;7(1):1–7. Available from: http://dx.doi.org/10.1038/s41598-017-13151-3.
27. Taefi A, Huang CC, Kolli K, et al. Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients. Hepatol Int. 2015;9(3):454–60.
28. Peck-Radosavljevic M. Thrombocytopenia in chronic liver dis ease. Liver Int. 2017;37(6):778–93.
29. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23(18):3228–39.
30. Xu WS, Qiu XM, Ou QS, et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation a noninva sive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis b. Med (United States). 2015;94(10):1–7.
31. Yuyun D, Zhihua T, Haijun W, et al. Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibro sis. Scand J Gastroenterol [Internet]. 2019;54(1):81–6. Available from: https://doi.org/10.1080/00365521.2018.1558786.
32. Ilhan E, Güvenç TS, Altay S, et al. Predictive value of red cell distribution width in intrahospital mortality and postinter vention thrombolysis in myocardial infarction flow in patients with acute anterior myocardial infarction. Coron Artery Dis. 2012;23(7):450–4.
33. Semba RD, Patel K V., Ferrucci L, et al. Serum antiox idants and inflammation predict red cell distribution width in older women: The Women’s Health and Aging Study I. Clin Nutr [Internet]. 2010;29(5):600–4. Available from: http://dx.doi.org/10.1016/j.clnu.2010.03.001.
34. Lippi G. Targher G, Montagnana M LG. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med . 2009 Apr:628–32.
35. Lou YF, Wang MY, Mao WL. Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B. PLoS One. 2012;7(5).
36. Han YQ, Zhang L, Yan L, et al. Red blood cell distribution width predicts long-term outcomes in sepsis patients admitted to the intensive care unit. Vol. 487, Clinica Chimica Acta. 2018. p. 112–6.
37. Kim HM, Kim BS, Cho YK et al. Elevated red cell distribution width is associated with advanced fibrosis in NAFLD. Clinical and molecular hepatology, 2013;19(3):258–65.
38. Hu Z De, Lippi G, Montagnana M. Diagnostic and prognostic value of red blood cell distribution width in sepsis: A narrative review. Clin Biochem [In ternet]. 2020;77(December 2019):1–6. Available from: https://doi.org/10.1016/j.clinbiochem.2020.01.001.
39. Montagnana M, Danese E. Red cell distribution width and can cer. Ann Transl Med. 2016;4(20):1–11.
40. Yang XZ, Gen AW, Xian JC, et al. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. Eur Rev Med Pharmacol Sci. 2018;22(2):479–85.
41. Lu LG, Zeng MD, Wan MB. et al. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic param eters. World J Gastroenterol. 2003;9(11):2574–8.
42. Hegazy M, Abo-Elfadl S, Mostafa A, et al. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease. Euroasian J Hepato-Gastroenterology. 2014;4(2):59–62.
43. Alam S, Noor-E-Alam SM, Chowdhury ZR, et al. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol. 2013;5(5):281–7.

APA	TAŞÇI Ş, Dilaver İ, saygın i, tok b (2023). Predictive value of biomarkers in steatohepatitis and fibrosis. , 493 - 498. 10.5455/annalsmedres.2023.02.047
Chicago	TAŞÇI ŞÜKRİYE,Dilaver İrem,saygın ismail,tok birgül Predictive value of biomarkers in steatohepatitis and fibrosis. (2023): 493 - 498. 10.5455/annalsmedres.2023.02.047
MLA	TAŞÇI ŞÜKRİYE,Dilaver İrem,saygın ismail,tok birgül Predictive value of biomarkers in steatohepatitis and fibrosis. , 2023, ss.493 - 498. 10.5455/annalsmedres.2023.02.047
AMA	TAŞÇI Ş,Dilaver İ,saygın i,tok b Predictive value of biomarkers in steatohepatitis and fibrosis. . 2023; 493 - 498. 10.5455/annalsmedres.2023.02.047
Vancouver	TAŞÇI Ş,Dilaver İ,saygın i,tok b Predictive value of biomarkers in steatohepatitis and fibrosis. . 2023; 493 - 498. 10.5455/annalsmedres.2023.02.047
IEEE	TAŞÇI Ş,Dilaver İ,saygın i,tok b "Predictive value of biomarkers in steatohepatitis and fibrosis." , ss.493 - 498, 2023. 10.5455/annalsmedres.2023.02.047
ISNAD	TAŞÇI, ŞÜKRİYE vd. "Predictive value of biomarkers in steatohepatitis and fibrosis". (2023), 493-498. https://doi.org/10.5455/annalsmedres.2023.02.047

APA	TAŞÇI Ş, Dilaver İ, saygın i, tok b (2023). Predictive value of biomarkers in steatohepatitis and fibrosis. Annals of Medical Research, 30(4), 493 - 498. 10.5455/annalsmedres.2023.02.047
Chicago	TAŞÇI ŞÜKRİYE,Dilaver İrem,saygın ismail,tok birgül Predictive value of biomarkers in steatohepatitis and fibrosis. Annals of Medical Research 30, no.4 (2023): 493 - 498. 10.5455/annalsmedres.2023.02.047
MLA	TAŞÇI ŞÜKRİYE,Dilaver İrem,saygın ismail,tok birgül Predictive value of biomarkers in steatohepatitis and fibrosis. Annals of Medical Research, vol.30, no.4, 2023, ss.493 - 498. 10.5455/annalsmedres.2023.02.047
AMA	TAŞÇI Ş,Dilaver İ,saygın i,tok b Predictive value of biomarkers in steatohepatitis and fibrosis. Annals of Medical Research. 2023; 30(4): 493 - 498. 10.5455/annalsmedres.2023.02.047
Vancouver	TAŞÇI Ş,Dilaver İ,saygın i,tok b Predictive value of biomarkers in steatohepatitis and fibrosis. Annals of Medical Research. 2023; 30(4): 493 - 498. 10.5455/annalsmedres.2023.02.047
IEEE	TAŞÇI Ş,Dilaver İ,saygın i,tok b "Predictive value of biomarkers in steatohepatitis and fibrosis." Annals of Medical Research, 30, ss.493 - 498, 2023. 10.5455/annalsmedres.2023.02.047
ISNAD	TAŞÇI, ŞÜKRİYE vd. "Predictive value of biomarkers in steatohepatitis and fibrosis". Annals of Medical Research 30/4 (2023), 493-498. https://doi.org/10.5455/annalsmedres.2023.02.047